Suppr超能文献

人DNA拓扑异构酶I的N端结构域与其底物的精氨酸-丝氨酸结构域之间的相互作用决定了SF2/ASF剪接因子的磷酸化。

Interaction between the N-terminal domain of human DNA topoisomerase I and the arginine-serine domain of its substrate determines phosphorylation of SF2/ASF splicing factor.

作者信息

Labourier E, Rossi F, Gallouzi I E, Allemand E, Divita G, Tazi J

机构信息

Institut de Génétique Moléculaire de Montpellier (IGM), UMR 5535 CNRS, Université Montpellier II, CNRS - BP 5051, 1919, route de Mende, F34293 Montpellier Cedex 5, France.

出版信息

Nucleic Acids Res. 1998 Jun 15;26(12):2955-62. doi: 10.1093/nar/26.12.2955.

Abstract

Human DNA topoisomerase I, known for its DNA-relaxing activity, is possibly one of the kinases phosphorylating members of the SR protein family of splicing factors, in vivo. Little is known about the mechanism of action of this novel kinase. Using the prototypical SR protein SF2/ASF (SRp30a) as model substrate, we demonstrate that serine residues phosphorylated by topo I/kinase exclusively located within the most extended arginine-serine repeats of the SF2/ASF RS domain. Unlike other kinases such as cdc2 and SRPK1, which also phosphorylated serines at the RS domain, topo I/kinase required several SR dipeptide repeats. These repeats possibly contribute to a versatile structure in the RS domain thereby facilitating phosphorylation. Furthermore, far-western, fluorescence spectroscopy and kinase assays using the SF2/ASF mutants, demonstrated that kinase activity and binding were tightly coupled. Since the deletion of N-terminal 174 amino acids of Topo I destroys SF2/ASF binding and kinase activity but not ATP binding, we conclude that at least two distinct domains of Topo I are necessary for kinase activity: one in the C-terminal region contributing to the ATP binding site and the other one in the N-terminal region that allows binding of SF2/ASF.

摘要

人类DNA拓扑异构酶I以其DNA松弛活性而闻名,在体内它可能是使剪接因子SR蛋白家族成员磷酸化的激酶之一。关于这种新型激酶的作用机制知之甚少。我们以典型的SR蛋白SF2/ASF(SRp30a)作为模型底物,证明拓扑异构酶I/激酶磷酸化的丝氨酸残基仅位于SF2/ASF RS结构域最延伸的精氨酸 - 丝氨酸重复序列内。与其他也能使RS结构域的丝氨酸磷酸化的激酶(如cdc2和SRPK1)不同,拓扑异构酶I/激酶需要几个SR二肽重复序列。这些重复序列可能有助于RS结构域形成一种通用结构,从而促进磷酸化。此外,使用SF2/ASF突变体进行的远western印迹、荧光光谱和激酶分析表明,激酶活性和结合紧密相关。由于拓扑异构酶I的N端174个氨基酸的缺失会破坏SF2/ASF的结合和激酶活性,但不影响ATP结合,我们得出结论,拓扑异构酶I的激酶活性至少需要两个不同的结构域:一个在C端区域,有助于形成ATP结合位点,另一个在N端区域,允许SF2/ASF结合。

相似文献

2
Regiospecific phosphorylation control of the SR protein ASF/SF2 by SRPK1.SRPK1对SR蛋白ASF/SF2的区域特异性磷酸化调控
J Mol Biol. 2009 Jul 24;390(4):618-34. doi: 10.1016/j.jmb.2009.05.060. Epub 2009 May 27.
10
Processive phosphorylation of alternative splicing factor/splicing factor 2.可变剪接因子/剪接因子2的持续磷酸化
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12601-6. doi: 10.1073/pnas.1635129100. Epub 2003 Oct 10.

引用本文的文献

1
R-loops, type I topoisomerases and cancer.R环、I型拓扑异构酶与癌症
NAR Cancer. 2023 Mar 3;5(1):zcad013. doi: 10.1093/narcan/zcad013. eCollection 2023 Mar.
6
High-throughput screening to enhance oncolytic virus immunotherapy.高通量筛选以增强溶瘤病毒免疫疗法。
Oncolytic Virother. 2016 Apr 5;5:15-25. doi: 10.2147/OV.S66217. eCollection 2016.
7
A structural perspective of RNA recognition by intrinsically disordered proteins.内在无序蛋白对RNA识别的结构视角
Cell Mol Life Sci. 2016 Nov;73(21):4075-84. doi: 10.1007/s00018-016-2283-1. Epub 2016 May 26.

本文引用的文献

6
SR proteins and splicing control.SR蛋白与剪接调控。
Genes Dev. 1996 Jul 1;10(13):1569-79. doi: 10.1101/gad.10.13.1569.
8
Modulation of DNA topoisomerase I activity by p53.p53对DNA拓扑异构酶I活性的调节
Biochemistry. 1996 May 7;35(18):5778-86. doi: 10.1021/bi952327w.
9
The domain organization of human topoisomerase I.人类拓扑异构酶I的结构域组织
J Biol Chem. 1996 Mar 29;271(13):7602-8. doi: 10.1074/jbc.271.13.7602.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验